| Filed On | Filing |
|---|---|
| 20 Oct 2026 | DEFA14A |
| 20 Oct 2026 |
Proxy statement: annual meeting on December 3, 2026
CEO pay $6.5M, down 75% · say-on-pay vote |
| 05 Oct 2026 |
8-K: Regulation FD Disclosure
The BB-301 pivotal trial remains on track to begin in mid-2027 |
| 30 Sep 2026 |
8-K: Changes in Registrant's Certifying Accountant
As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Y... |
| 24 Sep 2026 |
8-K: Changes in Registrant's Certifying Accountant
We are the former independent registered public accounting firm for Benitec Biopharma Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Cur... |
| 21 Sep 2026 | EFFECT |
| 14 Sep 2026 | S-3 |
| 14 Sep 2026 |
8-K: Results of Operations and Financial Condition
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated |
| 14 Sep 2026 | 10-K |
| 30 Jun 2026 |
Form 4: Buchi J Kevin, Director
Gave 51,813 shares as a gift |
| 29 May 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 28 May 2026 |
Form 4: Friedman David Matthew, Director
Granted 35,000 Options (right to buy) |
| 28 May 2026 |
Form 3: Friedman David Matthew, Director
No securities owned |
| 14 May 2026 | 10-Q |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition |
| 03 Apr 2026 | UPLOAD |
| 20 Mar 2026 | CORRESP |
| 20 Mar 2026 | 10-K/A |
| 24 Feb 2026 | UPLOAD |
| 12 Feb 2026 | 10-Q |
Loading...
